Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
Will the recent positive trend continue leading up to its next earnings release, or is Esperion Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Esperion Q4 Earnings & Revenues Beat Estimates Esperion incurred a loss per share of 50 cents in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 53 cents. The company had incurred a loss of 76 cents per share in the year-ago quarter. Esperion generated revenues of $32.3 million, up 72% year over year. The reported figure beat the Zacks Consensus Estimate of $26.8 million. Quarter in Detail Esperion has two FDA-approved drugs in its commercial portfolio — Nexletol and Nexlizet. The company records royalties on sales of its drugs in Europe and other ex-U.S. markets. Product revenues, solely from the United States, totaled $20.
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar [Yahoo! Finance]Yahoo! Finance
- Esperion to Report First Quarter 2024 Financial Results on May 7 [Yahoo! Finance]Yahoo! Finance
- Esperion to Report First Quarter 2024 Financial Results on May 7GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity [Yahoo! Finance]Yahoo! Finance
ESPR
Earnings
- 2/27/24 - Beat
ESPR
Sec Filings
- 4/11/24 - Form DEF
- 4/11/24 - Form ARS
- 3/15/24 - Form 4
- ESPR's page on the SEC website